Fool - Investing News
10 Oct 2026, 16:13 UTC · 2h ago
Impact · against what's priced in
The termination of the Cellares manufacturing agreement provides a minor negative catalyst for BMY. Otherwise, the financial updates for both Novo Nordisk and Bristol Myers Squibb reinforce existing market expectations regarding growth and stability.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
Bristol Myers Squibb terminated a manufacturing agreement with Cellares in August 2026.
Newoccurred in August 2026, published Oct 10 2026
More negative than 78% of claims this week
Novo Nordisk reported FY 2025 revenue of approximately $46.3 billion, a growth rate of roughly 6.4%.
Priced in
Continue reading
5 related stories
Maintaining a 6.4% revenue growth rate on a $46.3 billion base demonstrates the company's continued dominance in the obesity and diabetes markets.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatMaintaining a 6%+ growth rate on a ~$46B base adds nearly $3B in annual top-line expansion, supporting the current valuation multiple.
More positive than 54% of claims this week
Bristol Myers Squibb reported FY 2025 revenue of about $48.2 billion, a year-over-year decrease of roughly 0.2%.
Priced inanalysis of FY 2025 results
So whatFlat revenue growth combined with a 2.6x debt-to-equity ratio limits the company's capacity for aggressive M&A without further leveraging the balance sheet.
More negative than 63% of claims this week
Bristol Myers Squibb reported FY 2025 net income of approximately $7.1 billion, recovering from a net loss in the previous year.
Priced inanalysis of FY 2025 results
So whatThe return to profitability suggests stabilized operating costs, providing a floor for the 4.26% dividend yield.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company is described as a global leader with a dominant position in high-growth obesity and diabetes markets and strong revenue growth.
More positive than 52% of ticker scores this week
The company showed a recovery to net income after a previous loss, despite a slight decrease in annual revenue.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1h ago
—
NVO hasn't traded since this ran. Last close $38.64 (Oct 9); the reaction starts at the next open.
NVO chart →
